4Zhong N, Wang C, Yao W, et al. Prevalence of chnnic obstructive pulmonary lisease in China; a large, peoplelation - baded survey. Respir Crit Care Med,2007,176:753 - 760.
5Akkoca Yildi2 O, Onen 2P, DmikG, et. al. Is there any difference brtween effects of ipratropium bromide and formiterol on exercise capacity in moderate COPD. patient? Tuberk Toraks ,2006,54 : 105 - 113.
6Hanania NA, Donohue. JF. Phanmacologic interventions in chrinic obstractive pulmonary disease: bronchodilators. Proc Am Tlaorac Soc ,2007,4:526 - 534.
7Snow V, Laschor S, Mottur-Pilson C, etal. The evidence base for management of cecute exacerbations of COPD: clinical practive guideline,part I. echest,2001,119:1185 - 1190.
9GOLD Executive Committee[DB/OL]. Guidelines: Global Strategy for Diagnosis, Management, and Prevention of COPD,November 2006 [ 2006-11-18 ]. http://www.goldcopd.com/Guidelineitem. asp? 11 =2&12 = 1&intId =989.
10Celli BR, MacNee W, Committee members. Standard for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper. Eur Respir J, 2004,23:932-946.
